- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Xilio Therapeutics auf der Stifel Healthcare Conference: Pipeline-Fortschritte, klinische Validierung und Finanzierung bis 2028 | 1 | Investing.com Deutsch | ||
| Di | Xilio Therapeutics GAAP EPS of -$0.30 beats by $0.64, revenue of $9.98M beats by $5.06M | 2 | Seeking Alpha | ||
| Di | Xilio Therapeutics, Inc.: Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates | 2 | GlobeNewswire (USA) | ||
| Di | Xilio Therapeutics, Inc. Q3 Loss Drops | 4 | RTTNews | ||
| Di | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| Di | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Di | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.10. | Xilio doses first patient in lung cancer trial of XTX501 | 2 | Investing.com | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.10. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC | 1 | GlobeNewswire (USA) | ||
| 21.10. | Raymond James initiates Xilio Therapeutics stock with outperform rating | 1 | Investing.com | ||
| 02.10. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 28.09. | Xilio Names Yariv Houvras Chief Medical Officer | 1 | RTTNews | ||
| 28.09. | Xilio Therapeutics appoints Yariv Houvras as chief medical officer | 3 | Investing.com | ||
| 28.09. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer | 358 | GlobeNewswire (Europe) | WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people... ► Artikel lesen | |
| 02.09. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.08. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 12.08. | Xilio Therapeutics GAAP EPS of -$0.33, revenue of $18.7M | 2 | Seeking Alpha | ||
| 12.08. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08. | Xilio Therapeutics, Inc.: Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates | 449 | GlobeNewswire (Europe) | Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell... ► Artikel lesen | |
| 12.08. | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,623 | +0,81 % | Valneva meldet positive Phase-2-Daten für Shigellen-Impfstoff | Valneva hat mit seinem Impfstoffkandidaten S4V2 gegen Shigellose positive Ergebnisse aus zwei klinischen Phase-2-Studien erzielt. In einer US-amerikanischen Studie mit kontrollierter Infektion gesunder... ► Artikel lesen | |
| NOVAVAX | 9,050 | -0,88 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 6,980 | 0,00 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| OCUGEN | 0,882 | +4,01 % | Ocugen im Check: OCU400-Deal mit Celairis - jetzt zählt die nächste Stufe | ||
| VIVORYON THERAPEUTICS | 0,728 | +2,82 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,317 | +3,93 % | 200 Prozent Ausbeute, 1 geplanter GMP-Partner: Warum NurExone und Made Scientific die Exosomenproduktion skalieren wollen | ||
| SAREPTA THERAPEUTICS | 14,580 | -0,82 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,068 | +2,83 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 10-Q, Quarterly Report | ||
| REDHILL BIOPHARMA | 0,375 | -0,03 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| MYRIAD GENETICS | 5,010 | -1,34 % | Myriad Genetics auf der UBS Global Healthcare Conference: Strategischer Schwenk zur Onkologie vertieft | ||
| MANNKIND | 3,801 | +0,42 % | Cantor Fitzgerald hebt Kursziel für MannKind wegen Tyvaso-Dynamik auf 10 US-Dollar an | ||
| ONCO-INNOVATIONS | 0,141 | +10,52 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| NOVOCURE | 10,615 | +0,38 % | Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya for Brain Metastases from Non-Small Cell Lung Cancer | Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,900 | -0,84 % | Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028 | ||
| TRAWS PHARMA | 0,224 | -0,27 % | Traws Pharma, Inc. - S-1, General form for registration of securities |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 9,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.